Delphix เร่งการเติบโตและความสามารถในการทำกำไรเป็นปีที่สองติดต่อกัน

ความปลอดภัยของข้อมูลและการปฏิบัติตามข้อกำหนดผลักดันให้มีการใช้งานแพลตฟอร์มการจัดการข้อมูลการทดสอบ Delphix DevOps เพิ่มขึ้นอย่างรวดเร็ว

เรดวูดซิตี้ แคลิฟอร์เนีย, April 29, 2022 (GLOBE NEWSWIRE) —  Delphix ผู้นำอุตสาหกรรมในการจัดการข้อมูลการทดสอบ DevOps (TDM) ประกาศปิดปีงบประมาณ 2022 ด้วยการเติบโตของรายได้และความสามารถในการทำกำไรในระดับที่รวดเร็วเป็นปีที่สองติดต่อกัน โดยมีรายได้ประจำประจำปี (ARR) มากกว่า 100 ล้านเหรียญสหรัฐ

ด้วยกิจกรรมที่เพิ่มขึ้นจากประเทศที่เป็นศัตรูและแก๊งแรนซัมแวร์ บริษัทต่าง ๆ ทั่วโลกจึงต้องการโซลูชันในการทำให้ข้อมูลทดสอบเป็นอัตโนมัติและมีการรักษาความปลอดภัยสำหรับแอปพลิเคชันระดับองค์กร ด้วยเหตุนี้ ทำให้บริษัทมีการเติบโตของฐานลูกค้าองค์กรขนาดใหญ่ที่เติบโตเร็วขึ้น 36% เมื่อเทียบเป็นรายปี โดยได้แรงหนุนจากความเสี่ยงด้านข้อมูลที่เพิ่มขึ้น

การเติบโตของ Delphix เกิดขึ้นเนื่องจากบริษัทต่าง ๆ ทั่วโลกยังคงลงทุนในโซลูชัน DevOps ที่เป็นนวัตกรรมใหม่ๆ เพื่อเร่งการส่งมอบแอปพลิเคชัน ปรับปรุงโครงสร้างพื้นฐานแบบเดิมให้ทันสมัย และเคลื่อนย้ายแอปพลิเคชันต่าง ๆ ไปทั่วมัลติคลาวด์ Delphix นำเสนอแพลตฟอร์ม DevOps TDM เพียงแพลตฟอร์มเดียวที่ส่งมอบข้อมูลที่ปลอดภัยและเป็นไปตามข้อกำหนดสำหรับการทดสอบและการพัฒนาโดยอัตโนมัติ ทำให้สามารถสร้างสรรค์นวัตกรรมได้เร็วขึ้นถึง 10 เท่า

Jedidiah Yueh ผู้ก่อตั้งและซีอีโอของ Delphix กล่าวว่า “แอปพลิเคชันระดับองค์กรล้วนต้องการข้อมูลทดสอบเพื่อการเผยแพร่ที่รวดเร็วและมีคุณภาพ” “แต่ปกติแล้วข้อมูลการทดสอบจะช้า ซับซ้อน และเต็มไปด้วยความเสี่ยง Delphix ช่วยให้บริษัทต่างๆ เช่น Banco Carrefour, The University of Manchester และ BNP Paribas เปิดตัวแอปพลิเคชันต่างๆ ได้อย่างรวดเร็ว พร้อมทั้งได้ปรับปรุงความปลอดภัยและการปฏิบัติตามข้อกำหนดของข้อมูลไปด้วยกัน”

Banco Carrefour ในบราซิลใช้แพลตฟอร์มข้อมูล Delphix DevOps เพื่อเร่งการเปิดตัวแอปพลิเคชัน พร้อมทั้งได้มีการรับรองความปลอดภัยของข้อมูลและการปฏิบัติตามกฎระเบียบด้านความเป็นส่วนตัวไปด้วยกัน เช่น กฎหมายคุ้มครองข้อมูลทั่วไปของบราซิล (LGPD) Delphix เพิ่มขีดความสามารถให้ทีมพัฒนาด้วยความพร้อมใช้งานของข้อมูลที่เร็วขึ้นถึง 320 เท่าสำหรับการรายงานและการวิเคราะห์ทางการเงิน ช่วยให้ออกแอปพลิเคชันได้เร็วขึ้น และช่วยประหยัดพื้นที่จัดเก็บได้ถึง 70%

Delphix นำเสนอแพลตฟอร์มข้อมูล API ซึ่งเป็นนวัตกรรมใหม่ที่เปลี่ยนการส่งมอบแอปพลิเคชันด้วยการควบคุมข้อมูลที่ครอบคลุม Delphix ช่วยให้นักพัฒนาซอฟต์แวร์สร้างสรรค์สิ่งใหม่ ๆ ได้เร็วขึ้น ในขณะที่ลดความเสี่ยงในการปฏิบัติตามข้อกำหนดและความปลอดภัย โดยใช้การส่งข้อมูลแบบอัตโนมัติในสภาพแวดล้อมของการทดสอบ

Delphix ยังช่วยให้บริษัทกู้คืนข้อมูลจากการโจมตีของแรนซัมแวร์ได้เร็วขึ้น ด้วยการปกป้องข้อมูลอย่างต่อเนื่องและทำให้ข้อมูลในอดีตไม่เปลี่ยนแปลง

Yves Caseau ประธานเจ้าหน้าที่ฝ่ายดิจิทัลและสารสนเทศของกลุ่มบริษัท Michelin กล่าวว่า “เราเลือก Delphix เพราะเราชอบเทคโนโลยีที่ใช้เป็นเครื่องมือในการย้ายข้อมูลอย่างมีประสิทธิภาพจากที่หนึ่งไปยังอีกที่หนึ่ง เพื่อนำไปสร้างใหม่ และเพื่อเดินทางสู่อดีต” “หากเราดูสิ่งที่เราทำไปแล้ว เราใช้ Delphix เพื่อย้ายข้อมูลจากเซิร์ฟเวอร์ Exadata รุ่นเก่าไปยังเซิร์ฟเวอร์ Linux ของชุมชนเพื่อเพิ่มความสามารถในการปรับขนาดและใช้ต้นทุนต่ำลง”

Caseau กล่าวเสริมว่า “เรายังใช้ Delphix ในการเร่งนวัตกรรมและตั้งค่าสภาพแวดล้อมการทดสอบและการพัฒนาใหม่ให้เร็วขึ้น เราสามารถรับข้อมูลที่เหมาะสมทั้งหมดได้อย่างรวดเร็วด้วยพอยน์เตอร์เพียงไม่กี่ตัวและด้วยการคลิกเพียงแค่ไม่กี่ครั้ง อีกทั้งยังมีการถ่ายโอนข้อมูลเสมือนเมื่อเทียบกับข้อมูลที่มีอยู่จริง”

การจัดการข้อมูลการทดสอบเป็นองค์ประกอบที่สำคัญของการพัฒนาแอปพลิเคชัน แต่มักจะช้าและต้องทำด้วยตัวเอง แพลตฟอร์มข้อมูล Delphix DevOps ช่วยให้ทีมงานสามารถสร้าง จัดการ และทำให้สภาพแวดล้อมข้อมูลบนคลาวด์แบบไฮบริดเป็นแบบอัตโนมัติ เพื่อรองรับไปป์ไลน์ CI/CD และฝึกอัลกอริทึม AI/ML

Jim Mercer ผู้อำนวยการฝ่ายวิจัยของ DevOps และ DevSecOps ที่ IDC กล่าวว่า “ข้อมูลการทดสอบที่เป็นไปตามข้อกำหนดเป็นส่วนสำคัญของ DevOps และการทำให้มั่นใจว่าการเข้าถึงข้อมูลอย่างต่อเนื่องเป็นกุญแจสำคัญสำหรับองค์กรต่างๆ ในการเร่งการส่งมอบแอปพลิเคชัน” “เนื่องจากการเปลี่ยนผ่านสู่ดิจิทัลมีความจำเป็นมากขึ้นเรื่อย ๆ สำหรับองค์กรต่างๆ เพื่อแข่งขันในตลาดปัจจุบัน เราจึงยังคงเห็นถึงความต้องการโซลูชัน TDM ที่ทันสมัยในอุตสาหกรรมต่าง ๆ”

ไฮไลท์การเติบโตของ Delphix

Delphix ยังได้แนะนำนวัตกรรมหลายอย่างในการนำเสนอผลิตภัณฑ์ของบริษัทในปีงบประมาณที่แล้ว ได่แก่:

  • ห้องนิรภัยต่อเนื่องซึ่งเป็นความสามารถเฉพาะเพื่อแรนซัมแวร์ที่ช่วยเพิ่มความสามารถในการเก็บแยกข้อมูลจากกันของแพลตฟอร์ม Delphix และเสริมความแข็งแกร่งให้กับการปกป้องข้อมูลสำหรับองค์กร
  • ความสามารถในการปฏิบัติตามข้อมูลสำหรับลูกค้า Salesforceซึ่งช่วยปกป้องความเป็นส่วนตัวและความปลอดภัยของข้อมูลให้แก่ลูกค้า Salesforce ในขณะที่ยังช่วยปลดล็อกค่าในข้อมูล Salesforce ทั่วทั้งระบบคลาวด์และศูนย์ข้อมูลภายในองค์กร
  • หอควบคุมข้อมูลซึ่งให้จุดควบคุมเพียงจุดเดียวสำหรับระบบอัตโนมัติของข้อมูลการทดสอบที่ขับเคลื่อนด้วย API ทั่วทั้งไปป์ไลน์การพัฒนาตามขนาด
  • กำบังอัลกอริธึมสำหรับการปฏิบัติตามอย่างต่อเนื่องซึ่งนำเสนออัลกอริธึมระดับแนวหน้าของอุตสาหกรรมสำหรับการปกปิดข้อมูลที่ละเอียดอ่อนพร้อมกับ SDK ทำให้อัลกอริธึมที่กำหนดเองได้นั้นสามารถพัฒนาและดำเนินการได้อย่างอัตโนมัติ
  • การรวมระบบที่รับรองโดย SAP กับ SAP NetWeaver® และ SAP S/4HANA®ซึ่งช่วยให้ธุรกิจต่างๆ ใช้ Delphix เพื่อปกปิดและส่งข้อมูล SAP เสมือนจริงที่มีประสิทธิภาพผ่าน API ได้โดยอัตโนมัติ

เกี่ยวกับ Delphix

Delphix เป็นผู้นำในระบบอุตสาหกรรมการจัดเก็บข้อมูลการทดสอบ DevOps

ธุรกิจจำเป็นต้องเปลี่ยนรูปแบบการนำส่งแอปพลิเคชัน แต่ต้องใช้ความพยายามในการปรับความเร็วให้สมดุลกับการรักษาความปลอดภัยของข้อมูลและการปฏิบัติตามข้อบังคับ แพลตฟอร์มข้อมูล DevOps ของเราทำให้การรักษาความปลอดภัยข้อมูลเป็นแบบอัตโนมัติ ในขณะที่ปรับใช้ข้อมูลทดสอบอย่างรวดเร็วเพื่อเร่งการเปิดตัวแอปพลิเคชัน ด้วย Delphix ลูกค้าสามารถปรับแอปพลิเคชันให้ทันสมัย ปรับใช้มัลติคลาวด์ บรรลุ CI/CD และกู้คืนจากเหตุการณ์หยุดทำงาน เช่น แรนซัมแวร์ได้เร็วขึ้นสูงสุดถึง 2 เท่า

บริษัทชั้นนำ เช่น Choice Hotels, Banco Carrefour และ Fannie Mae ต่างก็ใช้ Delphix เพื่อเร่งการเปลี่ยนแปลงทางดิจิทัลและเปิดใช้งานการจัดการข้อมูลแบบ Zero trust เยี่ยมชมเราได้ที่ www.delphix.com ติดตามเราได้ที่ ลิงกต์อินทวิตเตอร์ และ เฟซบุ๊ก 

Josh Harbert

ประธานเจ้าหน้าที่ฝ่ายการตลาด                |        Delphix

913.972.6180

Philips successfully prices offering of Notes for EUR 2 billion

April 28, 2022

THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL, OR ANY SOLICITATION OF AN OFFER TO PURCHASE, ANY SECURITIES OF PHILIPS.

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its issue of EUR 750 million fixed rate notes due 2027 (“2027 Notes”), EUR 650 million Green Innovation Notes due 2029 and EUR 600 million Sustainability Innovation Notes due 2033 (together, the “Notes”) under its European Medium Term Note (EMTN) program (the “EMTN Offering”).

The net proceeds of the Notes will be used for Eligible Projects in accordance with Philips Green and Sustainability Innovation Bond Framework and, in the case of the 2027 Notes, for general corporate purposes. Pending the full allocation of the net proceeds of the Notes, Philips intends to optimize its short-term treasury liquidity profile by applying such net proceeds towards the following liability management transactions which were announced earlier today, all of which are subject to the successful completion of the EMTN Offering:

  • A tender offer for certain series of its outstanding U.S. Dollar-denominated bonds due 2025 and 2026;
  • A tender offer for certain series of its outstanding Euro-denominated notes due 2023, 2024 and 2025 (the “Euro Tender Offer”);
  • The proposed make-whole redemption of any of the Euro-denominated notes due 2023 and 2024 that are not purchased in the Euro Tender Offer (the “Euro Make-Whole Redemption”); and
  • The proposed agreement with the relevant counterparties for early settlement of the outstanding forward contracts entered into in the third quarter of 2021 under the share buyback program for capital reduction purposes announced on July 26, 2021 (the “Early Forward Settlement”). The acquisition of 19,571,218 shares through the settlement of these forward contracts would result in the early completion of the repurchase program. Philips would then expect to cancel a total of approximately 28.3 million shares (including shares acquired through open market purchases in December 2021 and January 2022 under the aforementioned share buyback program) in the course of 2022, representing 3.3% of Philips’ currently outstanding shares.

Any decision by Philips to redeem outstanding bonds in the Euro Make-Whole Redemptions, or to complete the Early Forward Settlement, will depend on various factors at that time.

The issue price for the 2027 Notes is 99.458% with a Coupon of 1.875%, resulting in a yield of 1.990%. The issue price for the Green Innovation Notes is 99.165% with a Coupon of 2.125%, resulting in a yield of 2.248%. The issue price for the Sustainability Innovation Notes is 99.473% with a Coupon of 2.625%, resulting in a yield of 2.681%.

Settlement and issue of the Notes is scheduled for 5 May 2022. Application has been made for the Notes to be listed on the Official List of the Luxembourg Stock Exchange and to trading on the regulated market of the Luxembourg Stock Exchange.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 5977055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the EMTN Offering, the USD Tender Offer, the Euro Tender Offer, the Euro Make-Whole Redemption and the Early Forward Settlement. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Important Information
This announcement is for informational purposes only and does not constitute or form part of any offer or invitation to sell, or any solicitation of an offer to purchase, any securities of Philips.  The securities offered in the EMTN Offering have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.  Neither the EMTN Offering nor the Euro Tender Offer is being made and will not be made directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality (including, without limitation, facsimile transmission, telex, telephone, email and other forms of electronic transmission) of interstate or foreign commerce of, or any facility of a national securities exchange of, or to owners of the subject securities who are located or resident in the United States or to U.S. Persons as defined in Regulation S of the Securities Act.

In the United Kingdom, this announcement is being distributed to, and is directed at, only (a) persons who have professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”); or (b) high net worth companies, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The Notes are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Notes will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents.

Manufacturer target market (MIFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs or UK PRIIPs key information document (KID) has been prepared as not available to retail in EEA or UK.

Bombardier to Report First Quarter 2022 Financial Results and Hold Virtual Annual and Special Meeting of Shareholders on Thursday, May 5, 2022

MONTREAL, April 28, 2022 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) will publish its financial results for the first quarter of 2022 on May 5, 2022. On the same day, Bombardier will hold its Annual and Special Meeting of Shareholders (“Meeting”) in a virtual format.

Quarterly Conference Call

On May 5, 2022, at 8:00 a.m. EDT, Bombardier will hold a webcast/conference call intended for investors and financial analysts to review the company’s financial results for the first quarter ended March 31, 2022.

A live webcast of the call and relevant financial charts will be available at https://ir.bombardier.com

Stakeholders wishing to listen to the presentation and subsequent question-and-answer period by telephone may dial one of the following conference call numbers:

In English:

Toll-free dial-in number (Canada/U.S.): 1-800-898-3989
Local dial-in number: 514-861-3304
International dial-in numbers

Participant passcode: 2230833#

In French (with translation):
Toll-free dial-in number (Canada/U.S.): 1-877-395-0279
Local dial-in number: 514-392-1587
International dial-in numbers

Participant passcode: 4427560#

Media Call

May 5, 2022, at 9:30 a.m. EDT, members of the media are invited to dial in to a short Question and Answer session following our quarterly earnings call and before the virtual Annual and Special Meeting of Shareholders. Éric Martel, President and Chief Executive Officer of Bombardier, will be available to answer your questions related to the Q1 2022 financial results.

Media who would like to attend the Q&A session are asked to RSVP by emailing heather.neale@aero.bombardier.com.

Bilingual:

Toll-free dial-in number (Canada/U.S.): 1-800-952-5114
Local dial-in number: 416-406-0743
International dial-in numbers

Participant passcode: 2423914#

Annual and Special Meeting of Shareholders

On May 5, 2022, at 10:30 a.m. EDT, Bombardier welcomes all registered shareholders and duly appointed proxyholders who wish to participate in the online Meeting to do so by joining the live webcast available at https://bombardier.com/en/agm2022. Only registered shareholders and duly appointed proxyholders will be allowed to vote and ask questions during the live Meeting. Non-registered shareholders, guests and media will be able to watch online via the live webcast available at the same link.

Instructions on how to vote and participate in the online Meeting, including submitting questions to management and to the Chairman of the Board of Directors of Bombardier, will be available on the Corporation’s website here and on the online Meeting platform. Bombardier encourages shareholders to vote and submit their proxies prior to the Meeting.

The live webcast and relevant documents for both the Annual and Special Meeting of Shareholders and the conference call will be available at https://bombardier.com/en/agm2022. A recording of the Meeting and the call will be posted on Bombardier’s website shortly after the end of the webcast.

About Bombardier
Bombardier is a global leader in aviation, focused on designing, manufacturing and servicing the world’s most exceptional business jets. Bombardier’s Challenger and Global aircraft families are renowned for their cutting-edge innovation, cabin design, performance and reliability. Bombardier has a worldwide fleet of approximately 5,000 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals. Bombardier aircraft are also trusted around the world in special-mission roles.

Headquartered in Montréal, Québec, Bombardier operates aerostructure, assembly and completion facilities in Canada, the United States and Mexico. The company’s robust customer support network includes facilities in strategic locations in the United States and Canada, as well as in the United Kingdom, Germany, France, Switzerland, Italy, Austria, the UAE, Singapore, China and an Australian facility opening in 2022.

For corporate news and information, including Bombardier’s Environmental, Social and Governance report, visit bombardier.com. Learn more about Bombardier’s industry-leading products and customer service network at businessaircraft.bombardier.com. Follow us on Twitter @Bombardier.

Bombardier is a registered trademark of Bombardier Inc. or its subsidiaries.

For Information

Francis Richer de La Flèche
Vice President
Financial Planning and Investor Relations
Bombardier
+514 855 5001 x13228
Anna Cristofaro
Manager
Communications
Bombardier
+1 514 855 8678

Azerbaijani currency rates for April 29

BAKU, Azerbaijan, April 29. The official exchange rate of the US dollar and the euro against the Azerbaijani manat as of April 29, 2022 was set at 1.7 and 1.7887 manat respectively, Trend reports with reference to the Central Bank of Azerbaijan (CBA).

The manat rate in relation to world currencies on April 29:

Currencies Official exchange rate

1 US dollar USD 1.7

1 euro EUR 1.7887

1 Australian dollar AUD 1.2159

1 Argentine peso ARS 0.0148

100 Belarus ruble BYN 0.6186

1 Brazil real BRL 0.3440

1 UAE dirham AED 0.4628

1 South African rand ZAR 0.1068

100 South Korean won KRW 0.1347

1 Czech koruna CZK 0.0728

1 Chilean peso CLP 0.1983

1 Chinese yuan CNY 0.2564

1 Danish krone DKK 0.2404

1 Georgian lari GEL 0.5574

1 Hong Kong dollar HKD 0.2166

1 Indian rupee INR 0.0222

1 British pound GBP 2.1249

100 Indonesian rupiah IDR 0.0117

100 Iranian rials IRR 0.0040

1 Swedish krona SEK 0.1729

1 Swiss franc CHF 1.7511

1 Israeli shekel ILS 0.5132

1 Canadian dollar CAD 1.3330

1 Kuwaiti dinar KWD 5.5431

1 Kazakh tenge KZT 0.0038

1 Kyrgyz som KGS 0.0202

100 Lebanese pound LBP 0.1125

1 Malaysian ringgit MYR 0.3902

1 Mexican peso MXN 0.0834

1 Moldovan leu MDL 0.0922

1 Egyptian pound EGP 0.0918

1 Norwegian krone NOK 0.1813

100 Uzbek soum UZS 0.0152

1 Polish zloty PLN 0.3817

1 Russian ruble RUB 0.0234

1 Singapore dollar SGD 1.2287

1 Saudi riyal SAR 0.4532

1 SDR (Special Drawing Rights of IMF) XDR 2.2779

1 Turkish lira TRY 0.1149

1 Taiwan dollar TWD 0.0577

1 Tajik somoni TJS 0.1363

1 New Turkmen manat TMT 0.4857

1 Ukrainian hryvna UAH 0.0562

100 Japanese yen JPY 1.3022

1 New Zealand dollar NZD 1.1078

Source: TREND News Agency

South Korea to End Outdoor Mask Mandate

South Korea said Friday it will lift its outdoor mask mandate next week in response to a steady drop in COVID-19 cases after an omicron-fueled surge.

The announcement comes after Seoul dropped almost all other social-distancing measures earlier this month, ending two years of strict requirements that put a massive strain on the country’s small businesses.

From Monday, residents will no longer be required to wear face masks outdoors unless attending an event with more than 50 participants, health authorities said.

“As social-distancing measures are lifted and the mask mandate is being adjusted, people are increasingly returning to their normal lives,” Jeong Eun-kyeong, director of Korea Disease Control and Prevention Agency (KDCA), told reporters.

“This is all thanks to the patience and cooperation of the people over a long period of time,” Jeong added.

South Korea’s incoming administration, headed by conservative president-elect Yoon Suk-y, on Friday criticized the decision to end the mask mandate as “premature,” questioning if it had been based solely on “virus prevention measures.”

Ahn Cheol-soo, chief of Yoon’s transition team, had previously said the new government planned to make a decision on the mandate in May.

South Korea reported 50,568 new coronavirus cases Friday, well down from the peak of more than 620,000 a day in mid-March.

The KDCA’s Jeong said there had been a “steady decrease” in COVID-19 cases for the past six weeks.

“The number of new critically ill patients is also decreasing,” she said, adding hospitals had enough beds to treat new inpatients.

More than 86% of South Korea’s 51 million people have been fully vaccinated, with the majority also receiving a booster shot.

About 22,700 people in the country have died from the coronavirus — a 0.13% fatality rate, one of the world’s lowest.

Source: Voice of America

Foreign Businesses Consider Leaving China Amid Lockdowns

Chris Mei has been stuck in his Shanghai flat for a month save for PCR testing and occasional volunteer work delivering food to neighbors. That will change in a couple of days when he boards his flight for a long-scheduled trip home to Portland, Oregon.

He uses Zoom to do factory inspections for his 2-year-old import-export firm, Shanghai Fanyi Industry, but he can’t complete all the orders for clients overseas. He’s locked down like most of the 26 million people in the city, along with some of the factories where he normally sources goods, such as artificial plants and solar lights.

“In terms of how’s business, it’s definitely affected us,” Mei said. “Clients abroad always have deadlines, especially for some of our products.” He continued, “For example, for a shipment that recently went out, we had a portion of the order canceled due to the fact that the factory, they were on lockdown as well, so we basically could only produce what they could, and then the remaining part of the order basically passed the client’s deadline in South America.”

Leaving a city in lockdown has become an expensive, multistep process. Mei, a U.S. citizen, applied for permission to leave Shanghai by getting a pass from his neighborhood committee. He then found a driver with special permission to take him to the airport during lockdown – for about six times the usual price of that ride.

Shanghai’s residents have been ordered to stay home since early April in response to a spike in COVID-19 infections. Last week, authorities began easing restrictions in parts of the city to restore economic activity.

Mei’s case is typical, analysts who follow China say. Large numbers of foreign businesspeople in China are planning on leaving the country, for now or for good. The lockdowns have hammered an economy already hobbled by the 4-year-old Sino-U.S. trade dispute, capital outflows and last year’s crackdown on tech giants.

On March 18, That’s Shanghai, a local magazine, reported the results of an online survey saying 85% of foreigners in the city would “rethink their future in China” because of the lockdowns. The survey found that 48% of respondents plan to leave China over the next year and that 37% would wait in case anti-pandemic measures improve.

Risk seems to be increasing

Shipments through seaports in Shanghai and the Chinese tech hub Shenzhen, which locked down in March, have slowed because of a lack of workers and a shortage of truckers who are allowed to move imports and exports around the country.

Larger businesses can afford to wait in case lockdowns ease and China resumes its robust economic growth, said Doug Barry, communications vice president with the U.S.-China Business Council, a 265-member advocacy group in Washington.

Smaller companies are having more trouble because they depend on China’s advanced contract manufacturing ecosystem and cannot easily relocate, Barry said. He said some businesses have closed temporarily because so many workers can’t report to their jobs.

Others have spent money to help feed workers and even let them stay overnight at workplaces so they can report to their jobs the next day.

Overseas-based company leaders are staying away from their China projects because of quarantine rules, he said.

“Business in some cases has come to a complete stop,” Barry said. “The risk seems to be increasing, and the unknowns are also increasing and you’re looking at bottom lines and the future of things, and you’re wondering what to do.”

While foreign businesspeople are thinking of leaving, the significance of China to outside companies can be seen in the numbers. Foreign businesses invested $173.5 billion in China last year, up from $163 billion in 2020 and $140 billion a year earlier, according to the United Nations Conference on Trade and Development’s latest report.

Just more than 1 million foreign companies were registered in China at the end of 2020.

Companies normally relocate in China for contract manufacturing – which is seen as professional yet inexpensive – or to sell cars, coffee, phones and fashion apparel to the massive consumer market.

Incentives to stay

Mei will be back in Shanghai after a couple of months at home. By then, he expects there will be a “more solid” response to COVID-19 with clarity about people’s mobility.

Some people he knows have been called back to work in May, he said.

William Frazier, a 58-year-old U.S.-born owner of a business advisory firm in Shanghai, has lived in the city continuously since 2002. He has no plans to leave the city even though he’s been locked down since March 16. Frazier has a spacious flat in a high-end compound, making life tolerable as he works though emails, phone and video conferences. The economic chaos has caused more clients to call him for information.

“No real significant impact, I would say, not for me,” Frazier said. “I don’t see hiccups. I see opportunities.”

Local officials in China want foreign investors to stay in the country, the U.S.-China Business Council has found. They are willing to meet and hear out American businesspeople, Barry said, though no government body has offered them any economic stimulus.

Sticking around will keep companies competitive after China returns to normal, he said.

If lockdowns in Shanghai end in May, more businesspeople are likely to stay in the city, said Yan Liang, professor and chair of economics at Willamette University in Salem, Oregon. Local and central government policymakers have the economic aftershocks of COVID-19 “on their radar,” she said.

“It’s just so important to be able to have a foothold in a large market like this,” Liang said. “And I think some of the sentiments (are) also that even though there are some maybe temporary or maybe more permanent slowdowns, the Chinese economy is still a really bright spot when you compare with other countries in the world.”

That makes the lure of the largest market in the world worth waiting for, for businesses that can afford to hold out until cities open again.

Source: Voice of America

Informa Pharma Intelligence and The American Society of Gene & Cell Therapy (ASGCT) Launches Gene, Cell & RNA Therapy Landscape Q1 2022 Quarterly Data Report

New Report Highlights Key Industry Trends in Pharmaceutical R&D

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) — Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, and The American Society of Gene & Cell Therapy (ASGCT), today announced the launch of the Gene, Cell & RNA Therapy Landscape Q1 2022 Quarterly Data Report. The Q1 2022 report assesses industry trends by examining approved gene, cell and RNA therapies, the pharmaceutical pipeline by company, most targeted therapeutic areas, and an overview of recent dealmaking and start-up funding.

Notable findings from the first quarterly report of the year include:

  • FDA Approvals – Since Q4 2021, one new genetically modified cell therapy has been approved and one new gene therapy has filed for approval. Carvykti, a CAR-T cell therapy developed by Legend Biotech and Johnson & Johnson, was approved for multiple myeloma in the U.S. and EtranaDez (etranacogene dezaparvovec), an AAV5 gene therapy developed by uniQure, was filed for approval in the EU and UK for hemophilia B.
  • Gene Therapy Pipeline Growth  Since Q1 2021, the gene therapy pipeline has increased by 16% with 3,579 therapies in development, ranging from preclinical through preregistration. A total of 1,986 gene therapies (including genetically modified cell therapies such as CAR T-cell therapies) are in development, accounting for 55% of gene, cell and RNA therapies; and 816 non-genetically modified cell therapies are in development, accounting for 22% of gene, cell and RNA therapies.
  • Most Targeted Therapeutic Areas  Oncology and rare diseases continue to be the top areas of gene therapy development in both the overall pipeline (preclinical to preregistration) and in the clinic (Phase I to preregistration). Development for rare diseases most commonly occurs in the oncology space, representing a majority of 52% compared to non-oncology rare disease gene therapy pipeline development.
  • Deal Making – A total of 123 deals were signed, a 15% decrease in volume from Q4 2021. Q1 2022 was the lowest quarter total within the last year, and acquisition and alliance volume quarter by quarter remained flat, while financings continue to trend down. Acquisitions were the only type of deal to increase in Q1 2022.
  • Start-up Financing – Start-up financing by gene, cell and RNA therapeutic companies remained steady in Q1 2022. A total of 15 companies raised seed or Series A financing, totaling an aggregate $507.8M. The overall deal-making total across alliance, acquisitions and financings saw a 15% decline. In the largest start-up financing, Cellino Biotech, a Harvard University spin-out, raised $80M to support its large-scale production of autologous and allogeneic cell therapies.

“Since we started putting these quarterly reports together in Q1 2021, we have seen the gene therapy pipeline steadily increase. Oncology and rare disease remain the most targeted therapeutic areas, and we continue to see a strong pipeline for CAR-T cell therapies for cancer indications,” said Ly Nguyen-Jatkoe, PhD, Executive Director, Americas, Informa Pharma Intelligence. “Rare diseases continue to be a focus for RNA therapies.”

“The continued approvals of gene and cell therapies has turned into one of the brightest spots in releasing this report each quarter,” said David Barrett, JD, CEO, the American Society of Gene & Cell Therapy (ASGCT). “With the approval of Carvykti in Q1 2022 and the ever-expanding pipeline, we’re exceptionally optimistic about the future of the field.”

All pipeline and trial insights were compiled using data from Pharma Intelligence’s Pharmaprojects™, and Trialtrove™, part of Citeline, which has been tracking global drug development since 1980. Deal, financing and catalyst data were derived from Biomedtracker™. For more information, or to view the current and past reports, visit Informa Pharma Intelligence or contact pharma@informa.com.

About The American Society of Gene & Cell Therapy (ASGCT)
The American Society of Gene & Cell Therapy (ASGCT) is the primary professional membership organization for scientists, physicians, patient advocates and other professionals with interest in gene and cell therapy.

Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies. ASGCT advances knowledge, awareness and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to benefit patients and society.

About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products — Datamonitor Healthcare™, Sitetrove™, Trialtrove™, Pharmaprojects™, Biomedtracker™, Scrip™, Pink Sheet™ and In Vivo™ — to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 400 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information, visit pharmaintelligence.informa.com

Media Contacts:
Diffusion PR for Informa Pharma Intelligence
informapharma@diffusionpr.com

Alex Wendland for The American Society of Gene & Cell Therapy (ASGCT)
AWendland@asgct.org

Delphix Accelerates Growth, Profitability for Second Consecutive Year at Scale

Data Security, Compliance Drive Urgent Adoption of Delphix DevOps Test Data Management Platform

REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) — Delphix, the industry leader in DevOps test data management (TDM), today announced closing fiscal year 2022 with a second consecutive year of accelerated revenue growth and profitability at a scale well over $100M in annual recurring revenue (ARR).

With increasing activity from hostile nation states and ransomware gangs, companies around the world need a solution to automate and secure test data for enterprise applications. As a result, the company also reported 36% faster year-over-year growth of its large, enterprise customer base driven by increasing data risks.

Delphix’s growth comes as companies around the world continue to invest in innovative DevOps solutions to accelerate application delivery, modernize legacy infrastructure, and move applications across the multicloud. Delphix offers the only DevOps TDM platform that automates the delivery of secure, compliant data for test and development, enabling up to 10x faster innovation.

“Enterprise applications all need test data for fast, quality releases,” said Jedidiah Yueh, Delphix Founder and CEO. “But test data has traditionally been slow, complex, and filled with risk. Delphix helps companies like Banco Carrefour, The University of Manchester, and BNP Paribas release applications quickly while improving data security and compliance.”

Banco Carrefour in Brazil utilizes the Delphix DevOps Data Platform to accelerate application releases while ensuring data security and compliance with privacy regulations such as Brazil’s General Data Protection Law (LGPD). Delphix empowers development teams with 320x faster data availability for financial reporting and analytics, enables faster application releases, and helps save 70% on storage.

Delphix delivers an innovative API-first data platform that transforms application delivery with comprehensive data controls. By automating data delivery into test environments, Delphix helps software developers innovate faster while reducing compliance and security risk.

Delphix also helps companies recover faster from ransomware attacks by continuously protecting data and making historical data immutable.

“We selected Delphix, because we like the technology as a tool to move data efficiently from one place to another, to reconstruct, to travel to the past,” said Yves Caseau, Group Chief Digital & Information Officer at Michelin. “If we look at what we’ve done, we used Delphix to move data from our Exadata server legacy to community Linux servers to get more scalability and lower cost.”

“We are also using Delphix as a way to accelerate innovation and set up new test and development environments faster. We can get all the appropriate data very fast with a few pointers and a few clicks and have a virtual transfer of the data as opposed to a physical one,” Caseau added.

Test data management is a critical component of application development but is often slow and manual. The Delphix DevOps Data Platform enables teams to create, manage, and automate hybrid cloud-based data environments to support CI/CD pipelines and train AI/ML algorithms.

“Compliant test data is the lifeblood of DevOps and ensuring continuous access to it is key for enterprises to accelerate application delivery,” said Jim Mercer, Research Director of DevOps and DevSecOps at IDC. “With digital transformation becoming increasingly essential for enterprises to compete across today’s marketplaces, we continue to see the need for modern TDM solutions across multiple industries.”

Delphix Growth Highlights

Delphix also introduced multiple innovations across the company’s product offerings in last fiscal year, including:

About Delphix

Delphix is the industry leader for DevOps test data management.

Businesses need to transform application delivery but struggle to balance speed with data security and compliance. Our DevOps Data Platform automates data security, while rapidly deploying test data to accelerate application releases. With Delphix, customers modernize applications, adopt multi-cloud, achieve CI/CD, and recover from downtime events such as ransomware up to 2x faster.

Leading companies, including Choice Hotels, Banco Carrefour, and Fannie Mae, use Delphix to accelerate digital transformation and enable zero trust data management. Visit us at www.delphix.com. Follow us on LinkedIn, Twitter, and Facebook.


Josh Harbert     
Chief Marketing Officer   |   Delphix
913.972.6180